AVANIR Pharmaceuticals Invites Investors to Fourth Quarter and Fiscal Year End Conference Call

ALISO VIEJO, Calif., November 28, 2007 - AVANIR Pharmaceuticals (NASDAQ: AVNR) today announced that it will release complete financial results for the three months and fiscal year ended September 30, 2007 before market open on Tuesday, December 11, 2007. Keith Katkin, President and Chief Executive Officer, Randall Kaye, M.D., Senior Vice President and Chief Medical Officer, and Martin Sturgeon, Vice President and Interim Chief Financial Officer, will host an investment community conference call that same day at 8:00 a.m. Pacific time / 11:00 a.m. Eastern time to discuss those results and answer questions.

Investors are invited to listen to the live webcast by visiting AVANIR's corporate website at www.avanir.com. To listen to the live call, please go to AVANIR's website prior to the start of the call to register, download and install the necessary audio software.

An archived copy of the webcast will be available on AVANIR's website for 30 days, and a telephone replay will be available through December 16, 2007, by dialing (800) 642-1687 (domestic) or (706) 645-9291 (international) and entering the conference ID number 25259159.


AVANIR Pharmaceuticals is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases. AVANIR's products and product candidates address therapeutic markets that include the central nervous system (CNS), inflammation and infectious diseases. AVANIR's lead product candidate, Zenvia, is being developed for the treatment of pseudobulbar affect (PBA) and is the subject of an approvable letter from the U.S. Food and Drug Administration (FDA) for that indication. AVANIR has obtained a Special Protocol Assessment from the FDA covering the design of a single confirmatory Phase III clinical trial testing lower-dose formulations of Zenvia in patients with PBA to address issues raised by the approvable letter. The Company expects to enroll the first PBA patient into this trial by the end of the 2007 calendar year. Additionally, in April 2007 AVANIR announced meeting all primary endpoints in a Phase III clinical trial with Zenvia in patients with diabetic peripheral neuropathic (DPN) pain. The Company plans to conduct a formal pharmacokinetic (PK) study to assess alternative lower-dose quinidine formulations of Zenvia for DPN pain that are intended to deliver similar efficacy and improved safety/tolerability versus the formulations previously tested for this indication. AVANIR has also licensed a compound to Novartis International Pharmaceuticals Ltd. for the treatment of inflammatory disease. AVANIR's infectious disease drug candidate, AVP-21D9, is a human monoclonal antibody in pre-clinical development for the treatment of anthrax with funding provided to date from NIH/NIAID grants. The Company's first commercialized product, Abreva®, is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com.

To be included on AVANIR's e-mail alert list; visit AVANIR's website or click on the link below: http://www.b2i.us/irpass.asp?BzID=958&to=ea&s=0

Lippert/Heilshorn & Associates, Inc.
Jody Cain (jcain@lhai.com)
Brandi Floberg (bfloberg@lhai.com)
Nov 28, 2007